University of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Fred Hutchinson Cancer Center, Radiation Oncology Division, Seattle, WA 98195, USA.
Future Oncol. 2024;20(33):2573-2588. doi: 10.1080/14796694.2024.2389769. Epub 2024 Sep 11.
Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.
转移性肾细胞癌(RCC)可表现为寡转移疾病,和/或在全身治疗后出现寡进展。减瘤和局部转移导向治疗选择包括手术切除、立体定向消融放疗和热消融。积极的局部治疗可能延迟全身治疗的开始或改变全身治疗方案,并改善临床结局。在这篇叙述性综述中,我们综合了目前关于局部治疗管理选择的实践指南和前瞻性数据,并强调了未来的研究。由于数据有限且存在异质性,患者选择和局部治疗技术的选择存在争议,患者可能受益于多学科评估。需要有明确纳入标准和相关终点的前瞻性对照试验来阐明不同方法的风险和获益。